<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103060</article-id><article-id pub-id-type="publisher-id">TCM-42803</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_63533232.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学的马齿苋治疗动脉粥样硬化作用机制研究
  Study on Mechanism of Portulacae Herba in Treatment of Atherosclerosis Based on Network Pharmacology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尚</surname><given-names>猛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>绍庆</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曲</surname><given-names>添星</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陆</surname><given-names>钊罡</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>锐</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>宁夏医科大学药学院，宁夏 银川；中国海洋大学医药学院，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>宁夏医科大学口腔医学院，宁夏 银川</addr-line></aff><aff id="aff6"><addr-line>宁夏回族自治区人民医院/西北民族大学第一附属医院药学部，宁夏 银川</addr-line></aff><aff id="aff3"><addr-line>宁夏医科大学公共卫生与管理学院，宁夏 银川</addr-line></aff><aff id="aff2"><addr-line>宁夏医科大学临床医学院，宁夏 银川</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff7"><addr-line>宁夏医科大学药学院，宁夏 银川；宁夏特色中医药现代化工程技术研究中心，宁夏 银川；宁夏医科大学回医药现代化教育部重点实验室，宁夏 银川；西南医科大学心血管医学研究所，医学电生理教育部重点实验室，四川 泸州</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>427</fpage><lpage>439</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：基于网络药理学方法探究马齿苋治疗动脉粥样硬化的作用机制。方法：通过TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform)数据库获取马齿苋的活性成分及作用靶点，根据ADME筛选其主要活性成分，通过String平台进行分析并利用Cytoscape3.7.2软件构建马齿苋主要活性成分与作用靶点的网络；收集Disgenet、OMIM、Drugbank数据库中动脉粥样硬化的靶点，通过String平台进行马齿苋与动脉粥样硬化共同靶点相互作用分析并利用Cytoscape3.7.2软件构建其PPI网络；采用Metascape平台进行“药物–成分–靶点”的基因功能与通路分析，通过CB-DOCK进行分子对接验证。结果：马齿苋的主要活性成分为槲皮素、山柰酚、木犀草素等10个，对应212个作用靶点。动脉粥样硬化有关的靶点1081个。马齿苋成分–动脉粥样硬化共同靶点有ALB、IL-6、TNF等108个，主要通路有流体剪切力与动脉粥样硬化途径、癌症的途径、TNF信号通路等。槲皮素、山柰酚、木犀草素分别与ALB、IL-6的对接得分均&lt; −5 kcal/mol，说明它们之间的分子对接能力均较好。结论：马齿苋通过多成分、多靶点、多通路参与动脉粥样硬化的调节。
  Objective: To analyze the mechanism of Portulacae Herba in the treatment of atherosclerosis based on network pharmacological method. Methods: The active components and action targets of Portulacae Herba were obtained from TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform) Database, and the main active components of TCM were screened according to ADME. The String platform was used for analysis, and Cytoscape3.7.2 software was used to construct the network of main active components and action targets of purslane. The main atherosclerosis targets were collected from Disgenet, OMIM and DRUGBank databases. Protein interaction analysis was performed on the String platform, and a PPI network of common targets of Portulacae Herba and atherosclerosis was constructed using Cytoscape3.7.2 software. Metascape platform was used to analyze the gene function and pathway of “drug-component-target”, and finally CB-dock was used for molecular docking verification. Results: The main active components of Portulacae Herba in the treatment of atherosclerosis were 10, including quercetin, kaempferol and luteolin, corresponding to 212 targets. There were 1081 targets associated with atherosclerosis. Portulacae Herba ingredients - common targets of atherosclerosis has propagated, IL-6, TNF, such as 108. The main pathways have fluid shear stress and atherosclerosis, cancer pathway, TNF signaling pathway and so on. The docking scores of quercetin, kaempferol and luteolin with ALB and IL-6 were all &lt; −5 kcal/mol, indicating that the molecular docking ability between them was good. Conclusion: Portulacae Herba is involved in the regulation of atherosclerosis through multi-component, multi-target and multi-pathway.
 
</p></abstract><kwd-group><kwd>马齿苋，动脉粥样硬化，网络药理学，分子对接, Portulacae Herba</kwd><kwd> Atherosclerosis</kwd><kwd> Network Pharmacology</kwd><kwd> Molecular Docking</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：基于网络药理学方法探究马齿苋治疗动脉粥样硬化的作用机制。方法：通过TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform)数据库获取马齿苋的活性成分及作用靶点，根据ADME筛选其主要活性成分，通过String平台进行分析并利用Cytoscape3.7.2软件构建马齿苋主要活性成分与作用靶点的网络；收集Disgenet、OMIM、Drugbank数据库中动脉粥样硬化的靶点，通过String平台进行马齿苋与动脉粥样硬化共同靶点相互作用分析并利用Cytoscape3.7.2软件构建其PPI网络；采用Metascape平台进行“药物–成分–靶点”的基因功能与通路分析，通过CB-DOCK进行分子对接验证。结果：马齿苋的主要活性成分为槲皮素、山柰酚、木犀草素等10个，对应212个作用靶点。动脉粥样硬化有关的靶点1081个。马齿苋成分–动脉粥样硬化共同靶点有ALB、IL-6、TNF等108个，主要通路有流体剪切力与动脉粥样硬化途径、癌症的途径、TNF信号通路等。槲皮素、山柰酚、木犀草素分别与ALB、IL-6的对接得分均&lt; −5 kcal/mol，说明它们之间的分子对接能力均较好。结论：马齿苋通过多成分、多靶点、多通路参与动脉粥样硬化的调节。</p></sec><sec id="s2"><title>关键词</title><p>马齿苋，动脉粥样硬化，网络药理学，分子对接</p></sec><sec id="s3"><title>Study on Mechanism of Portulacae Herba in Treatment of Atherosclerosis Based on Network Pharmacology</title><p>Xia Wang<sup>1</sup>, Meng Shang<sup>2</sup>, Shaoqing Sun<sup>3</sup>, Qiang Gao<sup>1</sup>, Tianxing Qu<sup>4,5</sup>, Zhaogang Lu<sup>6</sup>, Rui Wang<sup>4,7,8,9*</sup></p><p><sup>1</sup>School of Clinical Medicine, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>2</sup>School of Public Health and Management, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>3</sup>School of Stomatology, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>4</sup>School of Pharmacy, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>5</sup>School of Medicine and Pharmacy, Ocean University of China, Qingdao Shandong</p><p><sup>6</sup>Department of Pharmacy, People’s Hospital of Ningxia /First Affiliated Hospital of Northwest University for Nationalities, Yinchuan Ningxia</p><p><sup>7</sup>Ningxia Research Center for Modernization of Traditional Chinese Medicine Engineering Technology, Yinchuan Ningxia</p><p><sup>8</sup>Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>9</sup>Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research of Southwest Medical University, Luzhou Sichuan</p><p><img src="//html.hanspub.org/file/21-2270692x5_hanspub.png" /></p><p>Received: Apr. 12<sup>th</sup>, 2021; accepted: May 21<sup>st</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/21-2270692x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the mechanism of Portulacae Herba in the treatment of atherosclerosis based on network pharmacological method. Methods: The active components and action targets of Portulacae Herba were obtained from TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform) Database, and the main active components of TCM were screened according to ADME. The String platform was used for analysis, and Cytoscape3.7.2 software was used to construct the network of main active components and action targets of purslane. The main atherosclerosis targets were collected from Disgenet, OMIM and DRUGBank databases. Protein interaction analysis was performed on the String platform, and a PPI network of common targets of Portulacae Herba and atherosclerosis was constructed using Cytoscape3.7.2 software. Metascape platform was used to analyze the gene function and pathway of “drug-component-target”, and finally CB-dock was used for molecular docking verification. Results: The main active components of Portulacae Herba in the treatment of atherosclerosis were 10, including quercetin, kaempferol and luteolin, corresponding to 212 targets. There were 1081 targets associated with atherosclerosis. Portulacae Herba ingredients - common targets of atherosclerosis has propagated, IL-6, TNF, such as 108. The main pathways have fluid shear stress and atherosclerosis, cancer pathway, TNF signaling pathway and so on. The docking scores of quercetin, kaempferol and luteolin with ALB and IL-6 were all &lt; −5 kcal/mol, indicating that the molecular docking ability between them was good. Conclusion: Portulacae Herba is involved in the regulation of atherosclerosis through multi-component, multi-target and multi-pathway.</p><p>Keywords:Portulacae Herba, Atherosclerosis, Network Pharmacology, Molecular Docking</p><disp-formula id="hanspub.42803-formula23"><graphic xlink:href="//html.hanspub.org/file/21-2270692x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-2270692x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-2270692x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>动脉粥样硬化(Atherosclerosis, AS)是由促炎细胞因子、炎症信号通路、生物活性脂质和粘附分子介导的慢性炎症疾病 [<xref ref-type="bibr" rid="hanspub.42803-ref1">1</xref>]，被认为是心血管疾病(Cardiovascular disease, CVD)的主要潜在病因 [<xref ref-type="bibr" rid="hanspub.42803-ref2">2</xref>]。世界卫生组织的调查结果表明，2015年因缺血性脑卒中及冠心病病死的人数高达1500万 [<xref ref-type="bibr" rid="hanspub.42803-ref3">3</xref>]，而临床治疗动脉粥样硬化的一线药物他汀类具有横纹肌溶解等一系列不良反应 [<xref ref-type="bibr" rid="hanspub.42803-ref4">4</xref>]。</p><p>马齿苋(Portulacae Herba)别名马苋、蚂蚱菜、长命菜等，隶属于石竹目、马齿科，性寒、味酸。现代药理学研究已经从马齿苋中分离出黄酮类、生物碱、脂肪酸、萜类、固醇、维生素和矿物质等多种活性组分，具有抗炎、抗氧化剂等生物活性 [<xref ref-type="bibr" rid="hanspub.42803-ref5">5</xref>]，其中抗氧化作用是该植物生物医学活性的主要因素 [<xref ref-type="bibr" rid="hanspub.42803-ref6">6</xref>]，动物实验亦表明马齿苋有调节高血脂、抗动脉粥样硬化的显著优势 [<xref ref-type="bibr" rid="hanspub.42803-ref7">7</xref>]，但是很少有分子作用机理是已知的。</p><p>中药多成分、多靶点和整体作用的特征与网络药理学类似，近年来网络药理学技术成为研究由高脂血症和动脉粥样硬化等复杂因素作用疾病的一种重要研究方法 [<xref ref-type="bibr" rid="hanspub.42803-ref8">8</xref>]。因此本文通过网络药理学的方法，筛选马齿苋的主要活性成分及作用靶点，探析其在治疗动脉粥样硬化时的作用机制，希望为临床研究提供一定的理论基础。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 马齿苋活性成分的收集</title><p>药物在机体内需要经过ADME过程才能到达靶器官发挥药理活性。口服生物利用度(Oral Bioavailability, OB)、类药性(Drug-Likeness, DL)是评价中药成分ADME过程的关键参数。通过TCMSP数据库(http://tcmspw.com/)收集马齿苋所有的成分，并以OB ≥ 30%、DL ≥ 0.18作为条件筛选马齿苋的主要活性成分。</p></sec><sec id="s6_2"><title>2.2. 马齿苋主要成分相关蛋白靶点的获取</title><p>在TCMSP数据库中点击“Related Targets”，根据收集的主要成分的Mol ID，获得各个主要活性成分的相关靶点“Target name”。在Uniport数据库(http://www.uniprot.org/)中查找马齿苋各个主要活性成分靶点对应的靶蛋白并对所有靶点进行标准化、规范化，获取其对应的基因简称。将马齿苋主要活性成分–靶点及数据属性表格导入Cytoscape 3.7.2软件，构建马齿苋主要活性成分–靶点网络图，判断马齿苋发挥药效的主要活性成分。</p></sec><sec id="s6_3"><title>2.3. 动脉粥样硬化疾病靶点筛选</title><p>以“atherosclerosis”为关键词，分别在Disgenet (http://www.digenet.org/)、OMIM (http://www.omim.org/)数据库中搜索动脉粥样硬化有关的疾病靶点，用Uniprot数据库对收集的靶点进行靶点⁃人类基因名转换，并在Drugbank数据库(https://www.drugbank.ca)中寻找调治动脉粥样硬化的临床一线西药作用靶点予以补充。</p></sec><sec id="s6_4"><title>2.4. 马齿苋成分–动脉粥样硬化靶点PPI网络构建</title><p>为进一步明确马齿苋成分靶点与动脉粥样硬化靶点彼此之间的作用，通过R语言将二者取交集并制作韦恩图。将交集靶点导入String11.0 (https://string-db.org)，将物种(“Organism”)选定为智人(“Homo sapiens”)，以置信度分数score &gt; 0.4 ( medium confidence)为条件进行筛选，并隐藏无联系的节点，导出TSV格式文本。将该文件上传至Cytoscape3.7.2制作马齿苋主要活性成分的靶点–动脉粥样硬化靶点的PPI网络，利用“Network Analyzer”分析该网络有效成分及连接度(Degree)、集聚系数(Clustering Coefficient)、介度(Betweenness)及紧密度(Closenesss)等靶点的网络拓扑参数，并根据参数分析得到核心靶点。其中自由度(Degree)表示在PPI网络中与该节点直接相互作用的节点数目，点击“generate style from statistics”设置靶点大小反映自由度值。</p></sec><sec id="s6_5"><title>2.5. 马齿苋活性成分–动脉粥样硬化靶点功能与通路的富集分析</title><p>将马齿苋治疗动脉粥样硬化的靶点导入Metascape平台，选择物种(“Input as species”)为智人(“H.sapiens”)进行定制分析(“Custom Analysis”) 设置P &lt; 0.01，根据结果进行GO基因功能与KEGG代谢通路的富集分析。</p></sec><sec id="s6_6"><title>2.6. 分子对接验证</title><p>分析找出马齿苋–动脉粥样硬化靶点网络图中度值(degree)排名前2的靶点，在PDB数据库(https://www.rcsb.org/)中，选定物种为“Homo Sapines”，屏幕分辨率为2.0~2.5、2.5~3.0寻找靶点的PDB文件，在Zinc数据库(http://zinc.docking.org/)寻找马齿苋前3个活性成分的MOL2文件，通过CB-Dock (http://clab.labshare.cn/cb-dock/php/index.php)将2个靶点与马齿苋前3个活性成分进行对接，根据Vina Score值评价其对接情况。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 马齿苋活性成分的收集</title><p>依托TCMSP数据库共获得54个马齿苋的化学成分，根据OB ≥ 30%、DL ≥ 0.18的条件筛选出10个结果，分别为花生四烯酸、环烯醇、β-胡萝卜素、β-谷固醇、山柰酚、5,7-二羟基-2-(3-羟基-4-甲氧基苯基)苯并四氢吡喃-4-酮、木犀草素、异甜菜素、异甜菜甙和槲皮素，见表1，作为马齿苋的主要活性成分。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Information of the main active ingredients of Portulacae Herb</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >序号</th><th align="center" valign="middle" >MOL ID</th><th align="center" valign="middle" >Components</th><th align="center" valign="middle" >成分</th><th align="center" valign="middle" >OB (%)</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >MCX-01</td><td align="center" valign="middle" >MOL001439</td><td align="center" valign="middle" >arachidonic acid</td><td align="center" valign="middle" >花生四烯酸</td><td align="center" valign="middle" >45.57</td><td align="center" valign="middle" >0.20</td></tr><tr><td align="center" valign="middle" >MCX-02</td><td align="center" valign="middle" >MOL003578</td><td align="center" valign="middle" >cycloartenol</td><td align="center" valign="middle" >环烯醇</td><td align="center" valign="middle" >38.69</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >MCX-03</td><td align="center" valign="middle" >MOL002773</td><td align="center" valign="middle" >beta-carotene</td><td align="center" valign="middle" >β-胡萝卜素</td><td align="center" valign="middle" >37.18</td><td align="center" valign="middle" >0.58</td></tr><tr><td align="center" valign="middle" >MCX-04</td><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >β-谷固醇</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >MCX-05</td><td align="center" valign="middle" >MOL000422</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >山柰酚</td><td align="center" valign="middle" >41.88</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >MCX-06</td><td align="center" valign="middle" >MOL005100</td><td align="center" valign="middle" >C1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >47.74</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >MCX-07</td><td align="center" valign="middle" >MOL000006</td><td align="center" valign="middle" >luteolin</td><td align="center" valign="middle" >木犀草素</td><td align="center" valign="middle" >36.16</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >MCX-08</td><td align="center" valign="middle" >MOL006657</td><td align="center" valign="middle" >isobetanidin</td><td align="center" valign="middle" >异甜菜素</td><td align="center" valign="middle" >59.73</td><td align="center" valign="middle" >0.52</td></tr><tr><td align="center" valign="middle" >MCX-09</td><td align="center" valign="middle" >MOL006662</td><td align="center" valign="middle" >isobetanin_qt</td><td align="center" valign="middle" >异甜菜甙</td><td align="center" valign="middle" >30.16</td><td align="center" valign="middle" >0.52</td></tr><tr><td align="center" valign="middle" >MCX-10</td><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >槲皮素</td><td align="center" valign="middle" >46.43</td><td align="center" valign="middle" >0.28</td></tr></tbody></table></table-wrap><p>表1. 马齿苋的主要活性成分信息</p><p>注：C1为5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl) chroman-4-one，5,7-二羟基-2-(3-羟基-4-甲氧基苯基)苯并四氢吡喃-4-酮。</p></sec><sec id="s7_2"><title>3.2. 主要活性成分对应靶点的收集</title><p>基于TCMSP数据库筛选马齿苋10个主要活性成分对应的394个相关靶点，将靶点通过Uniprot数据库进行标准化并获得基因简称，删除重复的靶点名称后共获得212个靶点。将马齿苋主要活性成分和对应的靶点关系导入Cytoscape 3.7.2，获取马齿苋主要活性成分–靶标网络图，见图1。Cytoscape网络分析表明，槲皮素连接度(Degree)为144，介度(Betweenness Centrality)为0.6842紧密度(Closeness Centrality)为0.6022，基于此预测槲皮素为马齿苋治疗动脉粥样硬化的最主要成分，其次为山柰酚、木犀草素、花生四烯酸，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Main parameters of network nodes of Portulacae Herba’s active componen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >MOL ID</th><th align="center" valign="middle" >名称</th><th align="center" valign="middle" >连接度</th><th align="center" valign="middle" >介度</th><th align="center" valign="middle" >紧密度</th></tr></thead><tr><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >槲皮素</td><td align="center" valign="middle" >144</td><td align="center" valign="middle" >0.6842</td><td align="center" valign="middle" >0.6022</td></tr><tr><td align="center" valign="middle" >MOL000422</td><td align="center" valign="middle" >山柰酚</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >0.1572</td><td align="center" valign="middle" >0.4128</td></tr><tr><td align="center" valign="middle" >MOL000006</td><td align="center" valign="middle" >木犀草素</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >0.1536</td><td align="center" valign="middle" >0.4082</td></tr><tr><td align="center" valign="middle" >MOL001439</td><td align="center" valign="middle" >花生四烯酸</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >0.1929</td><td align="center" valign="middle" >0.3811</td></tr><tr><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >β-谷固醇</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >0.1270</td><td align="center" valign="middle" >0.3784</td></tr><tr><td align="center" valign="middle" >MOL002773</td><td align="center" valign="middle" >β-胡萝卜素</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >0.0457</td><td align="center" valign="middle" >0.3621</td></tr><tr><td align="center" valign="middle" >MOL005100</td><td align="center" valign="middle" >C1</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >0.0116</td><td align="center" valign="middle" >0.3471</td></tr><tr><td align="center" valign="middle" >MOL006657</td><td align="center" valign="middle" >异甜菜素</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.0162</td><td align="center" valign="middle" >0.3438</td></tr><tr><td align="center" valign="middle" >MOL006662</td><td align="center" valign="middle" >异甜菜甙</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.0028</td><td align="center" valign="middle" >0.3395</td></tr><tr><td align="center" valign="middle" >MOL003578</td><td align="center" valign="middle" >环烯醇</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>表2. 马齿苋活性成分网络节点主要参数</p><p>注：C1为5,7-二羟基-2-(3-羟基-4-甲氧基苯基)苯并四氢吡喃-4-酮。</p><p>图1. 马齿苋主要活性成分–靶点的PPI网络</p></sec><sec id="s7_3"><title>3.3. 动脉粥样硬化相关靶点的获取</title><p>在Disgenet数据库以GDA分数(Score gda) &gt; 0.01为标准，获得动脉粥样硬化有关靶点1016个，在OMIM数据库中获得动脉粥样硬化有关靶点142个，Drugbank数据库获得动脉粥样硬化有关靶点45个，去除重复项后共获得1081个动脉粥样硬化有关的靶点。</p></sec><sec id="s7_4"><title>3.4. 马齿苋成分–动脉粥样硬化靶点PPI网络构建</title><p>马齿苋活性成分靶点与动脉粥样硬化疾病靶点的韦恩图，见图2，得到马齿苋成分–动脉粥样硬化共同靶点108个，将这108个靶点导入String平台下载马齿苋–动脉粥样硬化作用靶点的TSV版本，导入Cytoscape3.7.2构建马齿苋–动脉粥样硬化靶点的PPI网络，见图3。结果显示ALB在网络中的连接度为87，介度为0.0662，紧密度为0.8480，预测ALB为马齿苋调治动脉粥样硬化的最重要靶点。IL-6、TNF、AKT1、VEGFA、CCL2、CXCL8、TP53、PTSG2同样是其相对重要的靶点，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Characteristic parameters of Portulacae Herba - atherosclerosis target network node</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >ID</th><th align="center" valign="middle" >靶点</th><th align="center" valign="middle" >连接度</th><th align="center" valign="middle" >介度</th><th align="center" valign="middle" >紧密度</th></tr></thead><tr><td align="center" valign="middle" >95</td><td align="center" valign="middle" >ALB</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.0662</td><td align="center" valign="middle" >0.8480</td></tr><tr><td align="center" valign="middle" >119</td><td align="center" valign="middle" >IL6</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.0461</td><td align="center" valign="middle" >0.8480</td></tr><tr><td align="center" valign="middle" >121</td><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >0.0320</td><td align="center" valign="middle" >0.8281</td></tr><tr><td align="center" valign="middle" >117</td><td align="center" valign="middle" >AKT1</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >0.0476</td><td align="center" valign="middle" >0.8217</td></tr><tr><td align="center" valign="middle" >223</td><td align="center" valign="middle" >VEGFA</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >0.0196</td><td align="center" valign="middle" >0.7794</td></tr><tr><td align="center" valign="middle" >79</td><td align="center" valign="middle" >CCL2</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >0.0271</td><td align="center" valign="middle" >0.7464</td></tr><tr><td align="center" valign="middle" >99</td><td align="center" valign="middle" >CXCL8</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >0.0135</td><td align="center" valign="middle" >0.7464</td></tr><tr><td align="center" valign="middle" >202</td><td align="center" valign="middle" >TP53</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >0.0283</td><td align="center" valign="middle" >0.7464</td></tr><tr><td align="center" valign="middle" >217</td><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >0.0179</td><td align="center" valign="middle" >0.7412</td></tr></tbody></table></table-wrap><p>表3. 马齿苋–动脉粥样硬化主要靶点网络节点特征参数</p><p>图2. 马齿苋成分–动脉粥样硬化靶点</p><p>图3. 马齿苋成分–动脉粥样硬化靶点PPI网络</p></sec><sec id="s7_5"><title>3.5. 靶点功能与通路的富集分析</title><p>运用Metascape数据平台对马齿苋调治动脉粥样硬化相关靶点进行信号通路分析，将物种和基因背景设置为智人，进行KEGG代谢通路富集分析，见图4(D)，按照Q值进行排序，前20个信号通路的具体信息和相对应的靶标见表4，KEGG结果表明马齿苋参与的主要通路有流体剪切力与动脉粥样硬化途径(Fluid shear stress and atherosclerosis)、癌症的途径(Pathways in cancer)、TNF信号通路(TNF signaling pathway)等。GO-BP结果显示马齿苋主要参与的生物学过程包括生物对脂多糖的反应(response to lipopolysaccharide)、对受伤的反应(response to wounding)、对无机物的反应(response to inorganic substance)、活性氧代谢过程(reactive oxygen species metabolic process)、积极调控细胞迁移(positive regulation of cell migration)、对细胞外刺激的反应(response to extracellular stimulus)，见图4(A)。</p><p>GO-MF结果显示相关靶点调节动脉粥样硬化的功能主要富集于细胞因子受体结合(cytokine receptor binding)、转录因子结合(transcription factor binding)、核受体活性(nuclear receptor activity)、脂质结合(lipid binding)、蛋白质均二聚活性(protein homodimerization activity)，蛋白质结构域特异性结合(protein domain specific bind)等，见图4(C)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Enrichment results of Portulacae Herba target pathway in regulating atherosclerosi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >GO</th><th align="center" valign="middle" >Description</th><th align="center" valign="middle" >Count</th><th align="center" valign="middle" >Log10 (q)</th><th align="center" valign="middle" >Hits</th></tr></thead><tr><td align="center" valign="middle" >ko05418</td><td align="center" valign="middle" >Fluid shear stress and atherosclerosis</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >−38.94</td><td align="center" valign="middle" >AKT1, BCL2, CAV1, CTNNB1, FOS, GSTM1, HMOX1, ICAM1, IFNG, IKBKB, IL1A, IL1B, MMP2, MMP9, NFE2L2, NOS3, PECAM1, PLAT, MAPK8, RELA, CCL2, SELE, THBD, TNF, TNFRSF1A, TP53, VCAM1, VEGFA, NCF1</td></tr><tr><td align="center" valign="middle" >hsa05200</td><td align="center" valign="middle" >Pathways in cancer</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >−34.98</td><td align="center" valign="middle" >AKT1, AKR1B1, AR, BCL2, CASP3, CASP9, CDKN1A, CTNNB1, EGF, EGFR, ELK1, FOS, GSTM1, HIF1A, HMOX1, IFNG, IGF2, IKBKB, IL4, IL6, CXCL8, MMP1, MMP2, MMP9, MYC, NFE2L2, NOS2, PPARD, PPARG, MAPK1, MAPK8, PTEN, PTGS2, RELA, RXRA, STAT1, TGFB1, TP53, VEGFA</td></tr><tr><td align="center" valign="middle" >hsa04668</td><td align="center" valign="middle" >TNF signaling pathway</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >−28.78</td><td align="center" valign="middle" >AKT1, CASP3, FOS, CXCL2, ICAM1, IKBKB, IL1B, IL6, CXCL10, IRF1, MMP3, MMP9, MAPK1, MAPK8, PTGS2, RELA, CCL2, SELE, TNF, TNFRSF1A, TNFRSF1B, VCAM1</td></tr><tr><td align="center" valign="middle" >ko05144</td><td align="center" valign="middle" >Malaria</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >−20.75</td><td align="center" valign="middle" >CD40LG, ICAM1, IFNG, IL1B, IL6, CXCL8, IL10, PECAM1, CCL2, SELE, SELP, TGFB1, TNF, VCAM1</td></tr><tr><td align="center" valign="middle" >ko05140</td><td align="center" valign="middle" >Leishmaniasis</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >−20.01</td><td align="center" valign="middle" >ELK1, FOS, IFNG, IL1A, IL1B, IL4, IL10, NOS2, MAPK1, PTGS2, RELA, STAT1, TGFB1, TNF, NCF1</td></tr><tr><td align="center" valign="middle" >hsa04066</td><td align="center" valign="middle" >HIF-1 signaling pathway</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >−20.00</td><td align="center" valign="middle" >AKT1, BCL2, CDKN1A, EGF, EGFR, F3, HIF1A, HMOX1, IFNG, IL6, INSR, NOS2, NOS3, SERPINE1, MAPK1, RELA, VEGFA</td></tr><tr><td align="center" valign="middle" >ko04064</td><td align="center" valign="middle" >NF-kappa B signaling pathway</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >−16.64</td><td align="center" valign="middle" >PARP1, BCL2, CD40LG, CXCL2, ICAM1, IKBKB, IL1B, CXCL8, PLAU, PTGS2, RELA, TNF, TNFRSF1A, VCAM1</td></tr><tr><td align="center" valign="middle" >hsa05169</td><td align="center" valign="middle" >Epstein-Barr virus infection</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >−14.82</td><td align="center" valign="middle" >AKT1, BCL2, CASP3, CASP9, CDKN1A, HSPB1, ICAM1, IFNG, IKBKB, IL6, IL10, CXCL10, MYC, MAPK8, RELA, STAT1, TNF, TP53</td></tr><tr><td align="center" valign="middle" >hsa04926</td><td align="center" valign="middle" >Relaxin signaling pathway</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >−14.61</td><td align="center" valign="middle" >AKT1, COL3A1, EGFR, FOS, MMP1, MMP2, MMP9, NOS2, NOS3, MAPK1, MAPK8, RELA, TGFB1, VEGFA</td></tr><tr><td align="center" valign="middle" >ko04210</td><td align="center" valign="middle" >Apoptosis</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >−14.53</td><td align="center" valign="middle" >PARP1, AKT1, BCL2, CASP3, CASP9, CTSD, FOS, IKBKB, MAPK1, MAPK8, RELA, TNF, TNFRSF1A, TP53</td></tr><tr><td align="center" valign="middle" >ko05202</td><td align="center" valign="middle" >Transcriptional misregulation in cancer</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >−12.96</td><td align="center" valign="middle" >CDKN1A, IGFBP3, IL6, CXCL8, MMP3, MMP9, MPO, MYC, PLAT, PLAU, PPARG, RELA, RXRA, TP53</td></tr><tr><td align="center" valign="middle" >ko04370</td><td align="center" valign="middle" >VEGF signaling pathway</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >−9.30</td><td align="center" valign="middle" >AKT1, CASP9, HSPB1, NOS3, PLA2G4A, MAPK1, PTGS2, VEGFA</td></tr><tr><td align="center" valign="middle" >hsa05216</td><td align="center" valign="middle" >Thyroid cancer</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >−8.99</td><td align="center" valign="middle" >CDKN1A, CTNNB1, MYC, PPARG, MAPK1, RXRA, TP53</td></tr><tr><td align="center" valign="middle" >ko05220</td><td align="center" valign="middle" >Chronic myeloid leukemia</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >−8.66</td><td align="center" valign="middle" >AKT1, CDKN1A, IKBKB, MYC, MAPK1, RELA, TGFB1, TP53</td></tr><tr><td align="center" valign="middle" >hsa04610</td><td align="center" valign="middle" >Complement and coagulation cascades</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >−6.49</td><td align="center" valign="middle" >F3, F7, CXCL10, SERPINE1, PLAT, PLAU, THBD</td></tr><tr><td align="center" valign="middle" >ko04670</td><td align="center" valign="middle" >Leukocyte transendothelial migration</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >−5.84</td><td align="center" valign="middle" >F3, F7, CXCL10, SERPINE1, PLAT, PLAU, THBD</td></tr><tr><td align="center" valign="middle" >ko05330</td><td align="center" valign="middle" >Allograft rejection</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >−5.79</td><td align="center" valign="middle" >CD40LG, IFNG, IL4, IL10, TNF</td></tr><tr><td align="center" valign="middle" >hsa04726</td><td align="center" valign="middle" >Serotonergic synapse</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >−5.73</td><td align="center" valign="middle" >ALOX5, APP, CASP3, PLA2G4A, MAPK1, PTGS1, PTGS2</td></tr><tr><td align="center" valign="middle" >hsa04015</td><td align="center" valign="middle" >Rap1 signaling pathway</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >−4.92</td><td align="center" valign="middle" >AKT1, CTNNB1, EGF, EGFR, IL6, INSR, MAPK1, VEGFA</td></tr><tr><td align="center" valign="middle" >hsa04923</td><td align="center" valign="middle" >Regulation of lipolysis in adipocytes</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >−4.92</td><td align="center" valign="middle" >ADRB2, AKT1, INSR, PTGS1, PTGS2</td></tr></tbody></table></table-wrap><p>表4. 马齿苋调治动脉粥样硬化靶点通路富集结果</p><p>图4. 马齿苋主要成分靶点的基因分析和通路富集</p></sec><sec id="s7_6"><title>3.6. 分子对接验证</title><p>靶点与活性成分的分子对接结果见表5，Morris GM等人的相关文章表明，若结合能低于−5.0 kcal/mol时，表示结合活性较为理想 [<xref ref-type="bibr" rid="hanspub.42803-ref9">9</xref>]，从表中可以看出槲皮素、山柰酚、木犀草素分别与主要靶点(ALB, IL-6)的对接得分均&lt; −5.0 kcal/mol，说明它们之间的分子对接能力均较好，分子对接模型如图5所示。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Molecular docking result</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >活性成分</th><th align="center" valign="middle"  colspan="2"  >Score(kcal/mol)</th></tr></thead><tr><td align="center" valign="middle" >ALB</td><td align="center" valign="middle" >IL-6</td></tr><tr><td align="center" valign="middle" >槲皮素</td><td align="center" valign="middle" >−7.8</td><td align="center" valign="middle" >−7.5</td></tr><tr><td align="center" valign="middle" >山柰酚</td><td align="center" valign="middle" >−8.7</td><td align="center" valign="middle" >−7.1</td></tr><tr><td align="center" valign="middle" >木犀草素</td><td align="center" valign="middle" >−8.7</td><td align="center" valign="middle" >−7.7</td></tr></tbody></table></table-wrap><p>表5. 分子对接结果</p><p>图5. (a) 槲皮素-ALB；(b) 山柰酚-ALB；(c) 木犀草素-ALB；(d) 槲皮素-IL-6；(e) 山柰酚-IL-6；(f) 木犀草素-IL-6</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>动脉粥样硬化的发病与形成是多细胞、多灶性的慢性炎症过程，亦是心血管疾病的主要潜在病因。中药化学成分复杂，主要是通过多种成分与多个靶标间相互协同作用来发挥药效，这与网络药理学的整体性、系统性等基本理论趋于一致 [<xref ref-type="bibr" rid="hanspub.42803-ref10">10</xref>]。将网络药理学应用于中药研究，既体现了大数据时代生物医药系统性研究的新趋势，又适应了中医药对系统性研究方法的迫切需求 [<xref ref-type="bibr" rid="hanspub.42803-ref11">11</xref>]。</p><p>本文基于网络药理学方法研究马齿苋治疗动脉粥样硬化的作用机制，初步筛选出马齿苋治疗动脉粥样硬化的主要活性成分为槲皮素、山柰酚、木犀草素等。动脉粥样硬化调节机理的研究说明，槲皮素可以通过调控MALAT1/miR-494-3p/PTEN轴减少氧化应激从而防止Ox-LDL诱导的HUVEC损伤 [<xref ref-type="bibr" rid="hanspub.42803-ref12">12</xref>]，另有研究表明，槲皮素具有显著的心脏相关益处，如不依赖内皮的血管舒张作用，减少粘附分子和其他炎性标记，在氧化应激条件下对一氧化氮和内皮功能的保护作用，预防神经元氧化和炎性损伤以及血小板的抗凝集作用 [<xref ref-type="bibr" rid="hanspub.42803-ref13">13</xref>]。山柰酚显著抑制ox-LDL诱导的巨噬细胞泡沫细胞的形成，导致分化簇36(CD36)蛋白水平、ATP结合盒(ABC)转运蛋白A1(ABCA1)、B类I型清道夫受体(SR-BI)和ABCG1蛋白水平降低 [<xref ref-type="bibr" rid="hanspub.42803-ref14">14</xref>]，从而发挥抗动脉粥样硬化作用。木犀草素通过调节信号转导子和转录激活因子3介导的炎症反应调治动脉粥样硬化 [<xref ref-type="bibr" rid="hanspub.42803-ref15">15</xref>]。因此槲皮素、山柰酚、木犀草素对治疗动脉粥样硬化具有重要意义。</p><p>马齿苋成分–动脉粥样硬化靶点PPI网络结果说明，马齿苋治疗动脉粥样硬化的主要靶点是ALB，而IL-6亦为重要靶点之一。动脉粥样硬化时血管收缩引起缺氧、缺血和氧化变化，导致循环中的游离白蛋白(ALB)转变为缺血修饰的白蛋白(IMA)，IMA是不良心血管事件发生的独立预测因子 [<xref ref-type="bibr" rid="hanspub.42803-ref16">16</xref>]。白介素6(IL-6)及其信号转导事件通过释放其他促炎细胞因子，磷脂酶氧化脂蛋白，刺激急性期蛋白分泌，血栓前介质的释放等多种机制促进动脉粥样硬化斑块的发展和斑块的去稳定 [<xref ref-type="bibr" rid="hanspub.42803-ref17">17</xref>]。亦有研究表明IL-6作为炎症细胞因子参与机体的炎症反应，其水平升高可促进血管内皮细胞及平滑肌细胞发生变性、坏死进而导致AS形成、粥样斑块破裂甚至血栓形成 [<xref ref-type="bibr" rid="hanspub.42803-ref18">18</xref>]。</p><p>GO富集及KEGG代谢通路结果表明马齿苋治疗动脉粥样硬化的主要通路有流体剪切力与动脉粥样硬化途径(Fluid shear stress and atherosclerosis)、癌症的途径(Pathways in cancer)、TNF信号通路(TNF signaling pathway)等。生理层流切应力对于正常的血管功能至关重要，动脉分叉、分支口和曲率附近切应力的紊乱或振荡流动与动脉粥样硬化的形成有关，因此剪切力对于调节动脉粥样硬化至关重要 [<xref ref-type="bibr" rid="hanspub.42803-ref19">19</xref>]。动脉粥样硬化与癌症中存在许多相互作用 [<xref ref-type="bibr" rid="hanspub.42803-ref20">20</xref>]，因此马齿苋可以通过调节癌症的途径从而调治动脉粥样硬化的发生。成熟的树突状细胞(DCs)衍生的外泌体通过膜TNF-α介导的NF-κB途径促进内皮炎症和动脉粥样硬化的发生 [<xref ref-type="bibr" rid="hanspub.42803-ref21">21</xref>]。分子对接验证结果亦说明，槲皮素、山柰酚、木犀草素与主要靶点(ALB, IL-6)的结合活性较强，再次对网络药理学所得到的结果进行验证，从而保证了本研究的可靠性。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本文通过网络药理学系统分析，得到包含槲皮素、山柰酚、木犀草素等10种马齿苋的主要活性成分，富集了流体剪切力与动脉粥样硬化途径、癌症的途径、TNF信号通路等多种通路，体现了马齿苋治疗动脉粥样硬化具有多成分、多通路、多靶点联合作用的特点，为马齿苋的实验开展提供了理论支持，同时也为其临床应用提供了参考。</p></sec><sec id="s10"><title>基金项目</title><p>宁夏自然科学基金(2019AAC03297)；西南医科大学心血管医学研究所开放基金(KeyME-2018-05)。</p></sec><sec id="s11"><title>文章引用</title><p>王 霞,尚 猛,孙绍庆,高 强,曲添星,陆钊罡,王 锐. 基于网络药理学的马齿苋治疗动脉粥样硬化作用机制研究Study on Mechanism of Portulacae Herba in Treatment of Atherosclerosis Based on Network Pharmacology[J]. 中医学, 2021, 10(03): 427-439. https://doi.org/10.12677/TCM.2021.103060</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42803-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Y.H., Xian, X.M., Wang, Z.Z., Bi, Y.C., Chen, Q.G., Han, X.F., et al. (2018) Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8, Article No. 80. &lt;br&gt;https://doi.org/10.3390/biom8030080</mixed-citation></ref><ref id="hanspub.42803-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ruiz-León, A.M., Lapuente, M., Estruch, R. and Casas, R. (2019) Clinical Advances in Immunonutrition and Atherosclerosis: A Review. Frontiers in Immunology, 10, Article No. 837. &lt;br&gt;https://doi.org/10.3389/fimmu.2019.00837</mixed-citation></ref><ref id="hanspub.42803-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">孔涛. 适合中国低收入人群高血压药物治疗方案的探索[D]: [博士学位论文]. 北京: 北京协和医学院, 2019.</mixed-citation></ref><ref id="hanspub.42803-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Simic, I. and Reiner, Z. (2015) Adverse Effects of Sta-tins—Myths and Reality. Current Pharmaceutical Design, 21, 1220-1226. &lt;br&gt;https://doi.org/10.2174/1381612820666141013134447</mixed-citation></ref><ref id="hanspub.42803-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y.X., Xin, H.L., Khalid, R., Wang, S.-J., Peng, C. and Zhang, H. (2015) Portulaca oleracea L.: A Review of Phytochemistry and Pharmacological Effects. Journal of Biomedicine and Biotechnology, 2015, Article ID: 925631. 
&lt;br&gt;https://doi.org/10.1155/2015/925631</mixed-citation></ref><ref id="hanspub.42803-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Parham, S., Kharazi, A.Z., Bakhsheshi-Rad, H.R., Nur, H., Ismail, A.F., Sharif, S., et al. (2020) Antioxidant, Antimicrobial and Antiviral Properties of Herbal Materials. Antioxidants, 9, Article No. 1309.  
&lt;br&gt;https://doi.org/10.3390/antiox9121309</mixed-citation></ref><ref id="hanspub.42803-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">赵仁宏, 赵心童, 贺圣文, 贺圣光, 王守训, 邵丽军. 马齿苋脂肪油对动脉粥样硬化大鼠胆固醇逆向转运相关基因表达的影响[J]. 中国慢性病预防与控制, 2013, 21(1): 12-14.</mixed-citation></ref><ref id="hanspub.42803-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">魏亚男, 朱博冉, 姬梦姣, 周童, 翟意, 薛文达, 等. 基于网络药理学探究补阳还五汤防治动脉粥样硬化的作用机制[J]. 中国药理学通报, 2020, 36(12): 1750-1755.</mixed-citation></ref><ref id="hanspub.42803-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">戚明珠, 张铌雪, 苏晓慧, 孔祥英. 黄芪甲苷治疗缺血性脑卒中的网络药理学[J]. 中国实验方剂学杂志, 2021, 27(3): 163-170.</mixed-citation></ref><ref id="hanspub.42803-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">段贤春, 黄石, 彭代银, 韩岚, 汪小莉, 汪永忠, 潘凌宇. 网络药理学在中药复方研究中的应用[J]. 中国药理学通报, 2020, 36(3): 303-308.</mixed-citation></ref><ref id="hanspub.42803-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, S. and Zhang, B. (2013) Traditional Chinese Medicine Network Pharmacology: Theory, Methodology and Application. Chinese Journal of Natural Medicines, 11, 110-120. &lt;br&gt;https://doi.org/10.3724/SP.J.1009.2013.00110</mixed-citation></ref><ref id="hanspub.42803-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李大鹏, 江杨, 李锋, 孙东晓. 槲皮素通过ceRNA调控PTEN/PI3K/AKT信号通路干预Ox-LDL诱导的HUVECs氧化应激损伤[C]//中国食品科学技术学会. 中国食品科学技术学会第十七届年会论文集. 中国食品科学技术学会, 2020: 211-212.</mixed-citation></ref><ref id="hanspub.42803-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Patel, R.V., Mistry, B.M., Shinde, S.K., Syed, R., Singh, V. and Shin, H.-S., (2018) Therapeutic Potential of Quercetin as a Cardiovascular Agent. European Journal of Medicinal Chemistry, 155, 889-904.  
&lt;br&gt;https://doi.org/10.1016/j.ejmech.2018.06.053</mixed-citation></ref><ref id="hanspub.42803-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Li, X.-Y., Kong, L.-X., Li, J., He, H.-X. and Zhou, Y.-D. (2013) Kaempferol Suppresses Lipid Accumulation in Macrophages through the Downregulation of Cluster of Differentiation36 and the Upregulation of Scavenger Receptor Class B Type I and ATP-Binding Cassette Transporters A1 and G1. International Journal of Molecular Medicine, 31, 331-338. &lt;br&gt;https://doi.org/10.3892/ijmm.2012.1204</mixed-citation></ref><ref id="hanspub.42803-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ding, X., Zheng, L., Yang, B., Wang, X. and Ying, Y. (2019) Luteolin Attenuates Atherosclerosis via Modulating Signal Transducer And Activator of Transcription 3-Mediated Inflammatory Response. Drug Design, Development and Therapy, 13, 3899-3911. &lt;br&gt;https://doi.org/10.2147/DDDT.S207185</mixed-citation></ref><ref id="hanspub.42803-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Adly, A.A.M., ElSherif, N.H.K., Ismail, E.A.R., Ibrahim, Y.A., Niazi, G. and Elmetwally, S.H. (2017) Ischemia-Modified Albumin as a Marker of Vascular Dysfunction and Subclinical Atherosclerosis in β-Thalassemia Major. Redox Report, 22, 430-438. &lt;br&gt;https://doi.org/10.1080/13510002.2017.1301624</mixed-citation></ref><ref id="hanspub.42803-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Schuett, H., Luchtefeld, M., Grothusen, C., Grote, K., Schieffer, B. (2009) How Much Is too Much? Interleukin-6 and Its Signalling in Atherosclerosis. Thrombosis &amp; Haemostasis, 101, 215-222. &lt;br&gt;https://doi.org/10.1160/TH09-05-0297</mixed-citation></ref><ref id="hanspub.42803-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bartekova, M., Radosinska, J., Jelemensky, M. and Dhalla, N.S. (2018) Role of Cytokines and Inflammation in Heart Function during Health and Disease. Heart Failure Reviews, 23, 733-758. &lt;br&gt;https://doi.org/10.1007/s10741-018-9716-x</mixed-citation></ref><ref id="hanspub.42803-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cunningham, K.S. and Gotlieb, A.I. (2005) The Role of Shear Stress in the Pathogenesis of Atherosclerosis. Laboratory Investigation, 85, 9-23. &lt;br&gt;https://doi.org/10.1038/labinvest.3700215</mixed-citation></ref><ref id="hanspub.42803-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Balzan, S. and Lubrano, V. (2018) LOX-1 Receptor: A Potential Link in Atherosclerosis and Cancer. Life Sciences, 198, 79-86. &lt;br&gt;https://doi.org/10.1016/j.lfs.2018.02.024</mixed-citation></ref><ref id="hanspub.42803-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gao, W., Liu, H., Yuan, J., Wu, C., Huang, D., Ma, Y., et al. (2016) Exosomes Derived from Mature Dendritic Cells Increase Endothelial Inflammation and Atherosclerosis via Membrane TNF-α Mediated NF-κB Pathway. Journal of Cellular &amp; Molecular Medicine, 20, 2318-2327. &lt;br&gt;https://doi.org/10.1111/jcmm.12923</mixed-citation></ref></ref-list></back></article>